Adjuvant IFN-α for Patients Underwent Curative Surgery for HCC With a Low miR-26 Expression
Phase 3 Unknown
296 enrolled
P2 Study of Postoperative Interferon/Fluorouracil vs Cisplatin/Fluorouracil for Hepatocellular Carcinoma.
Phase 2 Unknown
66 enrolled
MCLelderly
Phase 3 Unknown
570 enrolled
Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT
Phase 4 Unknown
40 enrolled
Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma
Phase 3 Unknown
300 enrolled
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Phase 2 Unknown
Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma
Phase 3 Unknown
750 enrolled
Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
Phase 2 Unknown
14 enrolled
Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
Phase 3 Unknown
800 enrolled
Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia
Phase 3 Unknown
1,000 enrolled
Combination Chemotherapy and Biological Therapy In Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed Surgically
Phase 2 Unknown
30 enrolled
Biological Therapy With Combination Chemotherapy in Patients With Colorectal Cancer
Phase 3 Unknown
1,050 enrolled
Fluorouracil and Biological Therapy in Treating Patients With Metastatic Kidney or Colorectal Cancer
Phase 1 Unknown
Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma
Phase 3 Unknown
Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma
Phase 3 Unknown
450 enrolled
Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer
Phase 3 Unknown
242 enrolled
Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma
Phase 3 Unknown
360 enrolled
Interferon Alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer
Phase 2 Unknown
90 enrolled
Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia
Phase 3 Unknown
750 enrolled
Cisplatin, Metronomic Low-Dose Interferon Alfa, Gemcitabine, and Fever-Range Whole-Body Hyperthermia in Treating Patients With Inoperable or Metastatic Pancreatic Cancer
Phase 2 Unknown
48 enrolled
High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma
Phase 3 Unknown
1,000 enrolled
FR-WB-TT/che
Phase 2 Unknown
36 enrolled
FR-WB-TT
Phase 2 Unknown
36 enrolled
Cisplatin, Gemcitabine, Interferon Alfa, and Hyperthermia in Treating Patients With Advanced Cancer
Phase 1/2 Unknown
30 enrolled